news
Targeting gene regulation may hold key to future Alzheimer’s therapies
Researchers have discovered that Alzheimer’s disease is driven by a deeper loss of gene regulation in brain cells – offering potential new targets for future therapies.
List view / Grid view
Alzheimer's disease (AD)
article
Inside the Alzheimer’s study backing stem cells, not drugs
In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are delivered intracerebroventricularly (directly into the brain) to address neuronal loss, while also reducing amyloid and tau biomarkers and improving cognition. Early data from this regenerative approach could help early drug discovery teams shape target selection, biomarker development and trial design.
article
Advanced drug development for neurodegenerative diseases with α-synuclein
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
news
Drug OLX-07010 shows promise in treating tau diseases
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
article
Promising Alzheimer’s drug earns FDA fast-track designation
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
news
Grant to fund development of vaccines to prevent dementia
Researchers at Washington University are developing a vaccine using nanofiber technology to prevent dementia, offering a safer and more effective alternative to current treatments.
news
Engineers target neurons with modified lipid nanoparticles
Researchers at the University of Pennsylvania have engineered lipid nanoparticles to target neurons, advancing mRNA treatments for brain diseases.
article
How AI will reshape pharma in 2025
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
news
Key enzyme discovery marks a step forward in Alzheimer’s treatment
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
news
Blood-brain barrier breakthrough for ALS and Alzheimer’s disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
news
Carbonic anhydrase inhibitors protect against tau protein build-up
The glaucoma drug methazolamide removed tau build-up and lessened signs of dementia in genetically-engineered zebrafish and mice.
article
Organoids: the versatile platform for discovery and regeneration
Anirban Datta, Head of Discovery Biology at Verseon International Corporation, details how recent breakthroughs are bringing once-distant possibilities, such as testing drugs more efficiently and restoring lost organ function through implantation, closer to reality.
article
Alzheimer’s disease: driving advancements with precision medicine
In this Q&A, Simon Lovestone, Vice President, Global Head, Neuroscience Discovery and Translational Science at Johnson & Johnson, shares how they are leveraging the A/T/N biomarker framework to achieve breakthroughs in Alzheimer’s disease research, in an aim to alter disease progression before daily life is significantly affected.
news
Specific HERV expression signatures linked to MS and ALS
The study identified which specific HERVs are important in increasing susceptibility for neurodegenerative diseases.
news
New toxic component in the evolution of Alzheimer’s disease
UBneuro scientists discovered that reducing RTP801 expression prevented cognitive deficits and inflammation.
